Nanoviricides, Inc. (NNVC)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.31
- As of
Kresmion compiles this page from NNVC's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
NANOVIRICIDES, INC. (NNVC): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-29.
See the full NNVC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NNVC on one page. Preview it with sample data, then open it live with a free account.
Preview the NNVC dossierActive signals for NNVC
- mediumEARNINGS_BEAT
Q4-2024: Beat consensus by 6.9% - EPS $-0.19 vs $-0.204 estimate
- mediumEARNINGS_BEAT
Q3-2024: Beat consensus by 17.4% - EPS $-0.16 vs $-0.1938 estimate
- mediumEARNINGS_BEAT
Beat consensus by 6.9% - EPS $-0.19 vs $-0.204 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 45.5% - EPS $-0.1 vs $-0.1836 estimate
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 23.0% - EPS $-0.11 vs $-0.1428 estimate
FREE, NO ACCOUNT
Every signal on NNVC, as it fires
New filings, 13F moves and cross asset signals on NNVC land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NNVC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 630087302 · 2026Q2 | $177K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NNVC
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
NNVC against its peers
NNVC's return on equity of -94.7% ranks in the 42nd percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | NNVC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 439500 USD | 17 | 8 |
| Operating margin | n/a | -7967.5% | n/a | 6 |
| Net margin | n/a | -727.6% | n/a | 6 |
| Return on equity | -94.7% | -91.7% | 42 | 12 |
| 1 year | -3.0% | -56.5% | 96 | 12 |
Peers (16): ATNM, ALGS, GNTA, MGX, BYSI, LITS, SGMO, TVGN, BRNS, GRCE, RNAZ, MCRB, FLNA, HOWL, IBO, QNCX. Left out: BCTX (period gap), EDSA (period gap), RLFTY (no annual filing), CLCS (period gap), CVM (period gap), SEOVF (no annual filing), IGC (no annual filing), VERU (period gap), MDNAF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NNVC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NNVC on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NNVC for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.